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The Semmes Weinstein monofilament
examination as a screening tool for diabetic
peripheral neuropathy
Yuzhe Feng, Felix J. Schlösser, MD, PhD, and Bauer E. Sumpio, MD, PhD, New Haven, Conn
Objective: The purpose of this systematic review is to evaluate current evidence in the literature on the efficacy of Semmes
Weinstein monofilament examination (SWME) in diagnosing diabetic peripheral neuropathy (DPN).
Methods: The PubMed database was searched through August 2008 for articles pertaining to DPN and SWME with no
language or publication date restrictions. Studies with original data comparing the diagnostic value of SWME with that
of one or more other modalities for DPN in patients with diabetes mellitus were analyzed. Data were extracted by two
independent investigators. Diagnostic values were calculated after classifying data by reference test, SWME methodology,
and diagnostic threshold.
Results: Of the 764 studies identified, 30 articles were selected, involving 8365 patients. There was great variation in both
the reference test and the methodology of SWME. However, current literature suggests that nerve conduction study
(NCS) is the gold standard for diagnosing DPN. Four studies were identified which directly compared SWME with NCS
and encompassed 1065 patients with, and 52 patients without diabetes mellitus. SWME had a sensitivity ranging from
57% (95% confidence interval [CI], 44% to 68%) to 93% (95% CI, 77% to 99%), specificity ranging from 75% (95% CI, 64%
to 84%) to 100% (95% CI, 63% to 100%), positive predictive value (PPV) ranging from 84% (95% CI, 74% to 90%) to 100%
(95% CI, 87% to 100%), and negative predictive value (NPV) ranging from 36% (95% CI, 29% to 43%) to 94% (95% CI,
91% to 96%).
Conclusions: There is great variation in the current literature regarding the diagnostic value of SWME as a result of different
methodologies. To maximize the diagnostic value of SWME, a three site test involving the plantar aspects of the great toe, the
third metatarsal, and the fifth metatarsals should be used. Screening is vital in identifying DPN early, enabling earlier
intervention and management to reduce the risk of ulceration and lower extremity amputation. (J Vasc Surg 2009;50:
675-82.)Diabetic peripheral sensory neuropathy (DPN) is a
significant independent risk factor for diabetic foot, which
is a major cause of foot ulcers and lower extremity ampu-
tations in patients with diabetes mellitus.1 Diabetic foot
ulcers have a lifelong incidence in patients with diabetes
mellitus of approximately 15% and are responsible for more
than 50% of nontraumatic lower limb amputations.2 Fol-
lowing the diagnosis of diabetes, strict glucose control can
be employed to prevent or delay the development of DPN.
An effective screening instrument is then required to diag-
nose DPN early in high risk patients to prevent future
ulceration and amputation.3,4
While physicians may use many quantitative methods
to detect peripheral neuropathy, the Semmes Weinstein
monofilament examination (SWME) is a noninvasive, low-
cost, rapid, and easy-to-apply test often used in clinical
testing and routine self assessment. The monofilaments are
applied to the test site perpendicularly until they bend for
about one second. Patients are instructed to say “yes” each
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doi:10.1016/j.jvs.2009.05.017time they sense the monofilament on their foot. If patients
fail to sense the monofilament after it bends, the test site is
considered to be insensate. Currently, Medicare only reim-
burses SWME as a part of the foot examination for the loss
of protective sensation, for which Medicare reimburses
$44.72.5,6 SWME is not reimbursed as a separate service,
often hindering accessibility to the test. The cost of dispos-
able monofilaments is merely around $0.50 each when
purchased from an independent supplier.7
The SWME has become closely associated with the
detection of DPN in both primary and specialty care over
the past five decades since its invention. In 1960, psychol-
ogists Florence Semmes and Sidney Weinstein developed a
set of nylon monofilaments to measure sensory loss in the
hand of patients with brain injury.8 Currently, the general
consensus regarding the definition of loss of protective
sensation involves inability to sense the 5.07/10 g Semmes
Weinstein monofilament. The gauge of this monofilament
is 5.07, a number derived from the logarithm of the applied
force inmilligrams.9 The buckling force for the 5.07mono-
filament is 10 grams, which is also the force felt by the
patient when the monofilament bends. However, in the
literature, the SWME test sites on the feet vary widely in
number and location.
Current literature has not integrated original data on
the diagnostic value of SWME. This systematic review
summarizes and critically evaluates evidence on the efficacy
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METHODS
Article selection. The search sequence was performed
in the Back66 file of the Medline Database via PubMed on
August 31, 2008 for titles and abstracts, resulting in 764
articles (Appendix, online only). All of these articles were
subsequently searched by two independent investigators
(Y.F. and F.S.) for relevance. The inclusion criteria for
selection of articles were: (1) domain of the study consisted
of patients with diabetes mellitus, (2) articles presented
original data on the application of the 5.07/10 g SWME
for diagnosis of DPN of the foot, and (3) the monofilament
test results were compared with one or more other modal-
ities in the diagnosis of DPN.No language restrictions were
applied. No publication date restrictions other than the
1966 starting date criterion were applied. Through this
process, 30 relevant articles were selected for analysis as
shown in Fig 1. The validity of the data in the selected artic-
les was determined according to the Oxford Center For
Evidence-Based Medicine’s levels of evidence.10
Statistical analysis. Data regarding the diagnostic
value of the 5.07/10 g SWME from each article were
collected. The sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV), true posi-
tives, false positives, true negatives, and false negatives were
obtained or calculated from the original data of each se-
lected study. After grouping the data by the presented
reference test, sub-classifications were created with the
methods of SWME application and the diagnostic thresh-
olds of SWME. If more than one study presented data with
the same reference test, method of application, and diag-
nostic threshold, meta-analyses were performed for the
diagnostic values of SWME from these articles. This calcu-
lation was done by adding the crude number of patients
that were true positives, false positives, true negatives, or
Fig 1. Summary of the article selection process.false negatives for each combination and then calculatingthe sensitivity, specificity, PPV, and NPV.11 This calcula-
tion was done only two times in lines F and I of Fig 2. All
other diagnostic values presented were derived from indi-
vidual studies.
RESULTS
The final selection process yielded 30 articles that
matched all of the inclusion criteria, involving a total of
8365 patients and 10 different reference tests. All selected
studies met the Oxford Center for Evidence-Based Medi-
cine’s evidence level10 of 2b or higher. There was a lack of
consensus in both the reference test used and the method-
ology of SWME in the identified studies. From these 30
articles, 16 provided sufficient original data, comparing
SWME with a reference test, to calculate the sensitivity,
specificity, PPV, NPV, true positives, false positives, true
negatives, and false negatives.12-27 While the other 14
studies fulfilled the inclusion criteria, they did not provide
enough data to calculate all of the above values.28-41 For
this reason, only the 16 studies with sufficient data were
used for data analysis while all 30 were used for qualitative
analysis. Fig 2 lists the quantitative data, including the
reference test, the articles, the study domain, the testing
methods, and the results of these studies. The 95% confi-
dence intervals for the sensitivity of SWME were calculated
for all 16 studies and graphed in Fig 3. Fig 4 shows the same
calculations for the specificity of SWME for the 16 studies.
To assess the accuracy of SWME in diagnosing DPN,
the results of SWME needed to be compared with a refer-
ence test. NCS was chosen as the most valid reference test
based on current literature.14,34 In the 16 studies with
sufficient data, the most frequent reference tests were his-
tory of ulceration with eight articles, and nerve conduction
study (NCS) with four studies. For each of these two
reference tests, five different methods of SWME application
and their associated sensitivity and specificity were pre-
sented. SWMEwas compared with the other four reference
tests by only one article each. The studies with NCS as the
reference test encompassed 1065 subjects with diabetic
mellitus along with 52 nondiabetic subjects. In two of the
studies, subjects without diabetes were used as controls and
were also listed in Fig 2. However, these subjects did not
contribute to the diagnostic values in the studies.
Considering all different methods and thresholds of
SWME that were described in these studies, SWME had a
sensitivity ranging from 57% (95% confidence interval [CI],
44% to 68%) to 93% (95% CI, 77% to 99%), specificity
ranging from 75% (95% CI, 64% to 84%) to 100% (95% CI,
63% to 100%), PPV ranging from 84% (95% CI, 74% to
90%) to 100% (95% CI, 87% to 100%), and NPV ranging
from 36% (95% CI, 29% to 43%) to 94% (95% CI, 91% to
96%) compared with NCS. The most sensitive method
involved testing the third and fifth metatarsal heads on each
foot with a positive test defined as the inability to sense either
site, resulting in a sensitivity of 93% (95% CI, 77% to 99%).
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in the literature. The first column shows the reference test that was used for the comparisons. The second column shows
specific descriptions of the study populations and detailed information regarding the methodology of SWME in the
identified articles. Articles with identical methods of SWME and reference tests were grouped. The last four columns
present the sensitivity, specificity, PPV, and NPV for each method of SWME given a specific reference test. SWME,
Semmes Weinstein monofilament examination;DM, diabetes mellitus;NDM, patients without diabetes mellitus in the
reference group; Sens., sensitivity; Spec., specificity; PPV, positive predictive value;NPV, negative predictive value; VPT,
vibration perception threshold. aThe fractions in the SWME column show the threshold for diagnosis/the number of
sites tested. Ex: 1/2 sites on each foot means the inability to detect one site out of two sites on each foot was considered
DPN. bThe calculations necessary for rows F and I were done by combining the crude number of subjects from all
studies in the specific category. cTwo positive out of the three tests: numbness in both legs; diminished reflex in both
legs; VPT score below 4.Fig 3. The sensitivities of SWME as indicated in Fig 2 are shown along with 95% CI. Letters in the horizontal axis
correspond to the “10 g SWME/Domain” column in Fig 2.
ig 2.
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Clinical relevance and main findings. Early identifi-
cation and management of DPN may reduce the risk of
ulceration and lower extremity amputation. Screening for
DPN in feet should be done on a regular basis with a
noninvasive semiquantitative examination by the patients
and their caretakers.15 The Center for Medicare and Med-
icaid Services, the International Diabetes Federation, and
the World Health Organization recommend that this test-
ing on the feet should be done by SWME.7,42-43
The quantitative analysis of the 16 studies with suffi-
cient data revealed that SWME is both fairly sensitive and
highly specific when compared with the gold standard of
NCS. Current literature on diagnosing DPN suggests that
NCS is the gold standard. NCS is used to identify patients
with peripheral neuropathy because it is objective and
sensitive. The test also measures quantitative neurophysio-
logic changes, and appears to be a reasonable surrogate
marker for neuropathy.34,44 In addition, the Diabetes Con-
trol and Complications Trial Research Group has demon-
strated that NCS can be successfully used in large, multi-
center clinical investigations of diabetic neuropathy.45 NCS
also is noted as the prima facie measure used for diagnosing
DPN.14 However, the clinical uses of NCS is limited due to
its expense and limited availability. Based on the Medicare
Fee Schedule for the nation in 2009, the global fee for each
NCS procedure is $61.31.46 In addition, the cost of obtain-
ing the electromyography equipment and supplies make the
procedure impractical for patients and physicians alike.
Diagnostic values of SWME vary significantly with dif-
ferent reference tests as the reference tests themselves vary
in effectiveness. This lack of consensus regarding the refer-
ence test was evident in the data collected. The secondmost
frequently used reference test, history of ulceration, yielded
lower sensitivity and specificity for SWME. For these results
to be valid, it was a necessary precondition that history of
ulceration be 100% indicative of DPN. This reference test,
Fig 4. The specificities of SWME as indicated in Fig 2
correspond to the “10 g SWME/Domain” column in Fhowever, did not meet this criterion since some cases weresecondary to vascular insufficiency without neuropathy.
Therefore, the lower diagnostic values revealed a worse
correlation between SWME and the history of ulceration,
but not necessarily a worse correlation between SWME and
DPN. The diagnostic values created by comparison of
SWME with the other four reference tests were only sup-
ported by one study each. Therefore, these correlations did
not reflect the relationships between SWME and DPN as
the diagnostic values of these references tests were un-
known. Different reference tests may classify patients in
different ways as their diagnostic powers vary. Therefore, it
is vitally important to select the most effective reference test
for comparison purposes.
SWME as a screening tool for DPN. While the use
of 5.07/10 g SWME is widespread and generally accepted,
there is still no standard method for the application of
SWME. The large variation in diagnostic value in the data
showed that many factors of SWME still need to be stan-
dardized in order to create a test that is highly reproducible.
Therefore, based on the current literature, we sought to
address the size of the monofilament, the testing sites, the
diagnostic threshold, and the accuracy of the test.
Regarding the size of the monofilament that is used in
SWME, all 30 selected articles used the 5.07/10 g mono-
filament to determine the loss of protective sensations.
Birke and Sims were the first to establish the threshold of
the 10 g monofilament in 1985.47 They used size 4.17,
5.07, and 6.28 monofilaments to detect sensation in 72
patients with leprosy and 28 patients with diabetic mellitus.
They concluded that the 5.07 monofilament is the thresh-
old for detecting protective sensation as no patients with
ulceration could sense the monofilament. Olmos et al
tested 199 patients with diabetic mellitus with monofila-
ments ranging from 0.0045 g to 447 g, concluding that the
5.07monofilament is also the best predictor of foot ulcer in
patients with diabetes mellitus.21 However, Sosenko et al
tested 314 patients using monofilaments ranging from
hown along with 95% CI. Letters in the horizontal axisare s1.65 g to 6.16 g, concluding that the 4.21 monofilament
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tion of whether the 4.21 monofilament could be more
sensitive; however, further testing by many others deter-
mined that the 5.07 monofilament best correlated with
DPN. The buckling force of the 4.21 monofilament is
normally considered to be within the range of normal
perception, not as the threshold. Holewski et al,48 Mueller
et al,28 and Kumar et al18 all obtained the same conclusion
that the 10 g buckling force of the 5.07monofilament is the
best threshold. Lastly, Rith-Najarian et al49 and Boyko et
al50 conducted large scale prospective studies to determine
that insensitivity to the 5.07 monofilament is an indepen-
dent predictor for foot ulceration. Several of the above
articles were not included in the final selection as they did
not meet the criterion of comparing the 10 g SWME with
other modalities of sensory testing.
The 30 selected studies used a variety of techniques to
detect neuropathy with SWME. Wide variation existed in
the number and location of the sites for testing. In the
original studies, selecting the number of sites for testing
seemed mostly arbitrary as most of these articles lack de-
tailed information on this aspect of the test. Without a
consensus on technique, number of testing sites varied
from one to ten. Lee et al evaluated the impact of each of
the ten possible sites in addition to combinations of sites.25
The sites included the dorsal surface between the base
of the first and second toes, the plantar aspect of the first,
third, fifth toes, the first, third, and fifth metatarsal heads,
the medial and later midfoot, and the heel. They found that
testing on all 10 sites and testing on the plantar aspects
of third and fifth metatarsal heads yielded the same sensi-
tivity of 93% and specificity of 100%. Throughout all stud-
ies, all examinations were preformed on the plantar aspect
of the foot except for the one dorsal site in testing with ten
sites. Another study on the diagnostic values of different
sites by McGill et al recommended that testing be done on
the first and fifth metatarsal heads. The sensitivity and
specificity for this combination of sites were 80% and 86%
respectively.51 In another study, Smieja et al concluded that
a four-site examination involving the first toe, the third
metatarsal head, and two other toes or metatarsal heads
produces 90% to 93% sensitivity.32 Mueller and Holewski
et al suggested that SWME should be performed in regions
at highest risk for skin breakdown, including the plantar
aspects of the metatarsal heads and the first toe.47,52
One point of consensus among all the studies is that all
SWMEwas carried out on the plantar aspect of the first toe.
Studies testing more than one site proceeded to test mostly
other toes and metatarsal heads. The number of sites tested
had an observable effect on the sensitivity of SWME. In the
group with history of ulceration as the reference test, the
four studies that used only one site16-19 had a sensitivity of
around 50%, considerably lower than other studies that
tested more than one site.20-23 In the NCS reference test
group, the two studies that only tested one site14,24 also
had sensitivities about 15% lower than methods that tested
more than one site.25 Testing more sites allowed the SWME
to be more sensitive in identifying patients with DPN. How-ever, testing more sites also has the consequence of taking
more time. The data showed that the number of sites tested
does not have the same effects on specificity. Considering the
need for both efficiency and efficacy, it is recommended that
SWMEbedone at least three sites on the plantar aspects of the
great toes, third and fifth metatarsal heads. This recommen-
dation derives from the highly sensitivity as described in Lee et
al, McGill et al, and Smieja et al.25,51,32
Another uncertainty in SWME involves the diagnostic
threshold, the number of incorrect responses necessary to
produce a positive test. In the selected studies, there was no
consensus for this threshold. The diagnostic threshold is
closely related to the sensitivity and specificity of the test. As
the number of incorrect answers necessary increases, the
sensitivity of the test decreases while the specificity increa-
ses.22 In 16 of the 30 selected studies, the diagnostic
threshold was set as one incorrect answer or inability to
detect one site.12,16-18,21,23,25,28-36 This conservative ap-
proach shows that the foot is at risk of DPN if any region
cannot sense the 5.07 monofilament. In the groups with
history of ulceration as the reference test, two categories
both tested eight sites with different thresholds as shown in
Fig 2. The test with one insensitive site as the threshold was
a more conservative approach and had a higher sensitivity
than the test with two sites as the threshold. Therefore, to
have the most sensitive screening, the most conservative
approach, with one insensitive site threshold should be
used. When considering specificity of these two categories,
the results were unexpected. The 1/8 sites method with a
more conservative threshold had a higher specificity than
the 2/8 sites method. The expected result was that the
conservative method would have a lower specificity as it
would have a higher false positive rate. This anomaly may
be due to the studies testing two different cohorts of
patients. In the groups with NCS as the reference test, two
of the categories both included one site with eight repeti-
tions. The more conservative threshold was the inability to
feel two repetitions while the other threshold was the
inability to feel five repetitions. In this case, the threshold
with inability to feel five repetitions was more sensitive.
While this result was somewhat counterintuitive, it showed
that repetitions at any one site were not as effective in
diagnosing DPN as using multiple different sites. This data
shows that testing one site multiple times is more subjective
as the patients expect the feeling at that site. This explana-
tion can also account for the very low specificity of the 2/8
site threshold in the NCS reference test group. Ultimately,
the most conservative thresholds with multiple site testing
are recommended to maximize sensitivity of SWME.
One great disadvantage of other modalities such as
pinprick and light touch is that the application of the
stimulus may be inconsistent, thus introducing possible
bias.32 Therefore, SWME, which applies a constant pres-
sure, is a more objective examination for the diagnosis of
DPN. Another one of the widely accepted modalities is
detection by vibration perception threshold (VPT) with
biothesiometer as it is objective and provides quantitative
measurements. However, poor repeatability of VPT test
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also impractical for widespread use as it is expensive, needs
calibration and a power source.18 Therefore, SWME is a
very practical screening instrument for the diagnosis of
DPN as its results are well correlated with NCS results if the
most sensitive methodology is applied.
The qualitative analysis of all 30 selected studies fo-
cused on the specific process of SWME testing. The
5.07/10 g Semmes Weinstein monofilament assesses the
integrity of Merkel touch domes and Meissner’s corpuscles
and their associated large diameter fibers.33 Sensitivity of
the test and the number of sites tested has positive correlation.
While more sites increases sensitivity, practical aspects regard-
ing the length of the examination also need to be taken into
consideration. Studies showed that three well chosen test sites
had close if not the same sensitivity as more sites.51 Lastly, the
diagnostic threshold for SWME should be set as one or more
insensate sites tomaximize sensitivity.With this threshold, any
foot with any insensate regions should be labeled as being at
risk ofDPN.Fromapublic health perspective, there ismore to
lose by failing to initiate preventive interventions in those who
would benefit than the alternative.
GENERAL RECOMMENDATIONS
This meta-analysis serves as a comprehensive review of
all the studies performed on the diagnostic properties of
SWME throughout the world. While many discrepancies
exist in the current literature regarding SWME, this review
seeks to present one standardized method of SWME with
the greatest sensitivity. Based on the current literature on
SWME, the optimal method is to use the 5.07/10 g
monofilament to test the plantar aspects of the great toe,
third, and fifth metatarsal heads. Patients unable to detect
one or more sites should be classified as at risk in order to
maximize sensitivity. Performed with this methodology,
the SWME can achieve sensitivity of 90% or above. In this
case, SWME can be an inexpensive, accurate, and painless
way for primary and specialty care physicians to identify
patients with DPN during a physical examination. The
SWME allows DPN to be diagnosed before obvious visual
signs such as foot deformities and calluses. We recommend
that SWME be used to identify DPN early on during routine
diabetic care. Once loss of protective sensation at any site is
identified by SWME, patients should be provided with an
intensive foot-care education program in addition to appro-
priate therapeutic footwear. Medicare currently covers one
pair of therapeutic shoes per year if there are documented
signs of nerve damage with calluses.54 It should be empha-
sized, however, that foot examinations are adjuncts and can-
not replace early detection of diabetes partnered with strict
glycemic control and close monitoring of hemoglobin A1c.
One possible deficiency is that this study did not report
the prevalence of DPN in the sample vs the population for
the domain of each study, which could affect the external
validity of the reported PPV and NPV. In addition, publi-
cation bias was not accounted for in this review. However,
for the purposes of this review, the main goal of assessingwhether SWME can be an effective tool in diagnosingDPN
was accomplished.
The variability in the methodology of SWME could
greatly limit the effectiveness of the test as a diagnostic
tool. However, this review found explanations that
would account for these variations. It is possible that
early DPN can affect sensory nerves differently in differ-
ent regions of the foot, thus leading to variation in the
data from the studies. Another cause of variation might
have been testing on sites with callus. These calluses
should be avoided when performing the SWME in order
to standardize results. Because more testing sites on the
foot and lower diagnostic thresholds lead to higher
sensitivity, variation in these two factors would lead to
different results in studies comparing different modali-
ties. However, more research is necessary in many areas
of SWME to produce data for quantitative analysis,
specifically regarding the number of sites, location of
sites, and the diagnostic threshold. In addition, further
experimentation is needed to compare the diagnostic
accuracy of SWME with that of other modalities such as
the tuning fork or the pinprick test given the gold
standard of NCS. A large cross-sectional study should
also be performed with the currently recommended
SWME method to validate its diagnostic value. This
method of SWME has great potential to be the first
alternative to NCS in the initial evaluation for clinically
significant neuropathy in patients with diabetes mellitus.
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